Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
Metrics to compare | RHHBY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRHHBYPeersSector | |
---|---|---|---|---|
P/E Ratio | 19.4x | 30.7x | −0.7x | |
PEG Ratio | −5.98 | −0.09 | 0.00 | |
Price/Book | 7.1x | 3.2x | 2.6x | |
Price / LTM Sales | 3.4x | 4.8x | 3.2x | |
Upside (Analyst Target) | 29.8% | 22.9% | 47.0% | |
Fair Value Upside | Unlock | 1.5% | 7.5% | Unlock |